Trial Profile
Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; IC9/CAR.19/IL15-transduced-CB-NK-cells (Primary) ; Mesna; Rimiducid
- Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2023 Status changed from active, no longer recruiting to completed.
- 01 Aug 2022 Planned End Date changed from 1 Jun 2022 to 30 Jun 2024.
- 01 Aug 2022 Planned primary completion date changed from 1 Jun 2022 to 30 Jun 2023.